Cytek BioSciences Inc’s recent filing unveils that its Chief Financial Officer McCombe William D. acquired Company’s shares for reported $97300.0 on Jun 02 ’25. In the deal valued at $2.78 per share,35,000 shares were bought. As a result of this transaction, McCombe William D. now holds 55,746 shares worth roughly $0.18 million.
TD Cowen downgraded its Cytek BioSciences Inc [CTKB] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Sell”. Stephens began covering CTKB with “an Overweight” recommendation on December 14, 2023. Raymond James started covering the stock on July 19, 2023. It rated CTKB as “a Mkt perform”.
Price Performance Review of CTKB
On Friday, Cytek BioSciences Inc [NASDAQ:CTKB] saw its stock fall -4.17% to $3.22. Over the last five days, the stock has lost -6.40%. Cytek BioSciences Inc shares have fallen nearly -50.39% since the year began. Nevertheless, the stocks have fallen -49.37% over the past one year. While a 52-week high of $7.63 was reached on 01/14/25, a 52-week low of $2.37 was recorded on 05/23/25.
Levels Of Support And Resistance For CTKB Stock
The 24-hour chart illustrates a support level at 3.14, which if violated will result in even more drops to 3.05. On the upside, there is a resistance level at 3.33. A further resistance level may holdings at 3.43.
How much short interest is there in Cytek BioSciences Inc?
A steep rise in short interest was recorded in Cytek BioSciences Inc stocks on 2025-05-30, growing by 1.22 million shares to a total of 5.41 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 4.19 million shares. There was a rise of 22.47%, which implies that there is a positive sentiment for the stock.
